Syreach notes actinium

NEW YORK, Jan. 13, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced the research collaboration with Astellas Pharma Inc. (TSE:4503) ("Astellas") to develop novel targeted radiotherapies using its Antibody Warhead Enabling (AWE) technology platform. Under this agreement, Actinium will utilize its AWE Platform technology to develop and characterize selected Astellas targeting agents labeled with the potent alpha-emitting radioisotope Actinium-225 (Ac-225). This collaboration is a component of Astellas' internal initiative to develop theranostics as part of its Rx+ ® business (For more information, please visit are excited to execute on this research collaboration with Astellas, a global leader at the forefront of healthcare innovation," stated Dr. Dale Ludwig, Chief Scientific and Technology Officer of Actinium. "Targeted radiotherapy has a highly differentiated mechanism of action with the potential to address multiple disease indications and therefore has been an area of significant exploration and investment of late. Through our AWE technology platform, we are able to bring our significant know-how in working with Actinium-225, as well as our robust clinical experience with targeted radiotherapies and supply chain to bear in this collaboration. With our enhanced laboratory capabilities and the expertise of our R&D team, we are well positioned to execute on this collaboration with Astellas as well as our own R&D strategy, to complement our Iomab-B and Actimab-A clinical programs."The intellectual property encompassing Actinium's AWE technology platform covers its gold standard linker technology, methods of ARC manufacture in addition to methods of use for ARCs in multiple diseases, including indication, dose and scheduling, radionuclide warhead, and therapeutic combinations. Actinium's AWE technology patent portfolio includes 30 patent families comprised of over 135 issued or pending global patent applications, of which 10 are issued and 24 pending in the United States.Sandesh Seth, Chairman and Chief Executive Officer of Actinium, added, "Through

Our development efforts, Actinium has established itself as a leader in the field of Actinium-225 based targeted radiotherapies. We have amassed the most experience treating patients with Actinium-225 via our CD33 program's several Actimab-A trials and have gained important insights in developing targeted radiotherapies through the execution of the Actimab-A and also SIERRA Phase 3 pivotal trial for our lead asset, Iomab-B. This expertise and experience with radiopharmaceuticals has been invaluable to us and we believe will also be to Astellas in this collaboration. As Iomab-B and Actimab-A advance in the clinic with multiple clinical milestones upcoming from each of our trials, we look forward to executing this collaboration and furthering the field of targeted radiotherapy with Astellas." About Our Antibody Warhead Enabling Platform TechnologyThe Antibody Warhead Enabling (AWE) Program has at its centerpiece the AWE Platform Technology. The Company's proprietary AWE Platform Technology is supported by intellectual property and know-how that enables the creation of Actinium-225 (Ac-225) Radio-Conjugates (ARCs) wherein a biomolecular targeting agent is stably labeled with the powerful Ac-225 payload to enhance targeted cell killing. The AWE Platform is protected by intellectual property covering the use of the "gold standard" chelator DOTA, and any conceivable derivative thereof. Additionally, Actinium holds intellectual property protection covering methods of chelation or labeling of the targeting agent with Ac-225, including newer next-generation methodologies for chelation of Ac-225.The AWE Program is structured to provide the opportunity for partners or collaborators to derive maximum value from a collaboration by leveraging Actinium's extensive technical know-how, access to its ARC drug development infrastructure and to its underlying AWE Platform Technology. The AWE Program provides a partner or collaborator with access to Actinium's knowledge bank and infrastructure allowing collaborators to benefit from accelerated development timelines for its ARCs.To learn more about the AWE Technology Platform or

Actinium Pharmaceuticals ( (ATNM) ) has released its Q3 earnings. Here is a breakdown of the information Actinium Pharmaceuticals presented to its investors.Actinium Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the development of targeted radiotherapies and Antibody Radiation Conjugates (ARCs) aimed at improving treatment outcomes for patients with high unmet medical needs, particularly in the field of hematology and oncology. In its latest earnings report for the quarter ending September 30, 2024, Actinium Pharmaceuticals highlighted the continuation of its research and development activities, despite reporting no revenue for the period. The company is focused on advancing its pipeline, which includes lead product candidates Iomab-B and Actimab-A, aimed at treating relapsed or refractory acute myeloid leukemia (AML).The financial metrics reveal a net loss of $11.6 million for the three months ended September 30, 2024, a reduction from the $13.3 million loss reported for the same period in 2023. This improvement in financial performance is attributed to a decrease in research and development expenses, which dropped to $9.8 million from $11.6 million in the previous year, and a reduction in general and administrative expenses. The company also raised $29.3 million through the sale of common stock, enhancing its cash position to $78.7 million.Actinium Pharmaceuticals remains committed to its strategic focus on developing radiotherapeutics for relapsed or refractory cancer patients. The management’s outlook is centered on advancing clinical trials for Iomab-B and Actimab-A, while also exploring new applications for its ARC platform in solid tumor indications. With an active research and development pipeline, the company aims to bring novel treatment options to market, addressing areas with significant unmet medical needs.Trending ArticlesClass Action Lawsuit Against Metagenomi Inc. (NASDAQ:MGX) DOJ to Push Alphabet’s Google to Sell Chrome Browser in Antitrust Move Super Micro Stock Soars 40% on Hiring New Auditor and Averting Delisting

Something that can run on one machine, run with the -regtest option.In regression test mode, blocks can be created on-demand; see qa/rpc-tests/ for teststhat run in -regtest mode.DEBUG_LOCKORDERActinium Core is a multithreaded application, and deadlocks or other multithreading bugscan be very difficult to track down. Compiling with -DDEBUG_LOCKORDER (configureCXXFLAGS="-DDEBUG_LOCKORDER -g") inserts run-time checks to keep track of which locksare held, and adds warnings to the debug.log file if inconsistencies are detected.Locking/mutex usage notesThe code is multi-threaded, and uses mutexes and theLOCK/TRY_LOCK macros to protect data structures.Deadlocks due to inconsistent lock ordering (thread 1 locks cs_mainand then cs_wallet, while thread 2 locks them in the opposite order:result, deadlock as each waits for the other to release its lock) area problem. Compile with -DDEBUG_LOCKORDER to get lock orderinconsistencies reported in the debug.log file.Re-architecting the core code so there are better-defined interfacesbetween the various components is a goal, with any necessary lockingdone by the components (e.g. see the self-contained CKeyStore classand its cs_KeyStore lock for example).ThreadsThreadScriptCheck : Verifies block scripts.ThreadImport : Loads blocks from blk*.dat files or bootstrap.dat.StartNode : Starts other threads.ThreadDNSAddressSeed : Loads addresses of peers from the DNS.ThreadMapPort : Universal plug-and-play startup/shutdownThreadSocketHandler : Sends/Receives data from peers on port 9333.ThreadOpenAddedConnections : Opens network connections to added nodes.ThreadOpenConnections : Initiates new connections to peers.ThreadMessageHandler : Higher-level message handling (sending and receiving).DumpAddresses : Dumps IP addresses of nodes to peers.dat.ThreadFlushWalletDB : Close the wallet.dat file if it hasn't been used in 500ms.ThreadRPCServer : Remote procedure call handler, listens on port 9332 for connections and services them.ActiniumMiner : Generates actiniums (if wallet is enabled).Shutdown : Does an orderly shutdown of everything.Ignoring IDE/editor filesIn closed-source environments in which everyone uses the same IDE it is commonto add temporary files it produces to the project-wide .gitignore file.However, in open source software such as Actinium Core, where everyone usestheir own editors/IDE/tools, it is less common. Only you know what files youreditor produces and this may change from version to version. The canonical wayto do this is thus to create your local gitignore. Add this to ~/.gitconfig:[core] excludesfile = /home/.../.gitignore_global(alternatively, type the command git config --global core.excludesfile ~/.gitignore_globalon a terminal)Then put your favourite tool's temporary filenames in that file, e.g.Another option is to create a per-repository excludes file .git/info/exclude.These are not committed but apply only to one repository.If a set of tools is used by the build system or scripts the repository (forexample, lcov) it is perfectly acceptable to add its files to .gitignoreand commit them.Development guidelinesA few non-style-related recommendations for developers, as well as points topay attention to for reviewers of Actinium Core code.General Actinium CoreNew features should be exposed on RPC first, then can be made available in the GUIRationale: RPC allows for better automatic testing.

The AWE Program please contact our Business Development team at dludwig-bd@actiniumpharma.com. About Astellas Pharma, Inc.'s Rx + ® Business Rx+ ® business: A business that leverages the expertise and knowledge of Astellas, which has been cultivated through its prescription drug (Rx) business, integrates innovative medical technology with cutting-edge technology in different fields, contributes to patients through Patient Journey (overall medical care, including diagnostic, preventive, therapeutic, and prognostic care), and creates new revenue streams separate from Astellas' core Rx products. For more information, please visit About Actinium Pharmaceuticals, Inc. (NYSE: ATNM)Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium's lead application for our ARCs is targeted conditioning, which is intended to selectively deplete a patient's disease or cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, Gene Therapy or Adoptive Cell Therapy (ACT) such as CAR-T to enable engraftment of these transplanted cells with minimal toxicities. With our ARC approach, we seek to improve patient outcomes and access to these potentially curative treatments by eliminating or reducing the non-targeted chemotherapy that is used for conditioning in standard practice currently. Our lead product candidate, I-131 apamistamab (Iomab-B) is being studied in the ongoing pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning. The SIERRA trial is over seventy-five percent enrolled and positive single-agent, feasibility and safety data has been highlighted at ASH, TCT, ASCO and SOHO annual meetings. More information on this Phase 3 clinical trial can be found at sierratrial.com. I-131 apamistamab will also be studied as a targeted conditioning agent in a Phase 1 study with a CD19 CAR T-cell Therapy and Phase 1/2 anti-HIV stem